Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?
Neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH) may have a common pathogenic mechanism; therefore, it has been suggested that known triggering agents for MH (such as succinylcholine) should be avoided in patients with NMS. Electroconvulsive therapy (ECT) continues to play a major therapeutic role in contemporary psychiatry, and succinylcholine has been the muscle relaxant of choice in attenuating violent muscle contractions induced by ECT. Mivacurium is a non-depolarizing muscle relaxant with a relatively rapid onset and a short duration of action, and to date it has been proved safe in MH-susceptible patients. In this case report, following succinylcholine use during ECT, a patient with NMS developed an increase in temperature and serum creatine kinase (CK) level, possibly due to an MH reaction. Since the patient's mental status necessitated further ECT, mivacurium was administered during subsequent treatment and resulted in effective attenuation of muscle contractions without elevation of patient temperature or CK levels. In addition, there was no marked prolongation of the anaesthetic. Mivacurium is a suitable agent for patients with NMS undergoing ECT, as it has not been associated with precipitation of an MH response.
Department of Anesthesiology, Yale University School of Medicine, New Haven, CT 06510.
D
D
Kelly
S J
SJ
Brull
D000328:Adult; D000771:Anesthesia, Intravenous; D001714:Bipolar Disorder / Q000628:therapy; D003402:Creatine Kinase / Q000097:blood; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage*; D008305:Malignant Hyperthermia / Q000097:blood / Q000517:prevention & control*; D000077590:Mivacurium; D009459:Neuroleptic Malignant Syndrome / Q000097:blood / Q000517:prevention & control*; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage*; D013390:Succinylcholine / Q000008:administration & dosage / Q000009:adverse effects*
D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D000077590:Mivacurium; D003402:Creatine Kinase; D013390:Succinylcholine